These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23716545)

  • 21. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
    Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
    Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.
    Fonseca R; Bergsagel PL; Drach J; Shaughnessy J; Gutierrez N; Stewart AK; Morgan G; Van Ness B; Chesi M; Minvielle S; Neri A; Barlogie B; Kuehl WM; Liebisch P; Davies F; Chen-Kiang S; Durie BG; Carrasco R; Sezer O; Reiman T; Pilarski L; Avet-Loiseau H;
    Leukemia; 2009 Dec; 23(12):2210-21. PubMed ID: 19798094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene.
    Tanner MM; Karhu RA; Nupponen NN; Borg A; Baldetorp B; Pejovic T; Fernö M; Killander D; Isola JJ
    Am J Pathol; 1998 Jul; 153(1):191-9. PubMed ID: 9665480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.
    Chng WJ; Van Wier SA; Ahmann GJ; Winkler JM; Jalal SM; Bergsagel PL; Chesi M; Trendle MC; Oken MM; Blood E; Henderson K; Santana-Dávila R; Kyle RA; Gertz MA; Lacy MQ; Dispenzieri A; Greipp PR; Fonseca R
    Blood; 2005 Sep; 106(6):2156-61. PubMed ID: 15920009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
    Chng WJ; Kumar S; Vanwier S; Ahmann G; Price-Troska T; Henderson K; Chung TH; Kim S; Mulligan G; Bryant B; Carpten J; Gertz M; Rajkumar SV; Lacy M; Dispenzieri A; Kyle R; Greipp P; Bergsagel PL; Fonseca R
    Cancer Res; 2007 Apr; 67(7):2982-9. PubMed ID: 17409404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma.
    Debes-Marun CS; Dewald GW; Bryant S; Picken E; Santana-Dávila R; González-Paz N; Winkler JM; Kyle RA; Gertz MA; Witzig TE; Dispenzieri A; Lacy MQ; Rajkumar SV; Lust JA; Greipp PR; Fonseca R
    Leukemia; 2003 Feb; 17(2):427-36. PubMed ID: 12592343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma.
    Morgan RJ; Gonchoroff NJ; Katzmann JA; Witzig TE; Kyle RA; Greipp PR
    Am J Hematol; 1989 Apr; 30(4):195-200. PubMed ID: 2929579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single nucleotide polymorphism array-based signature of low hypodiploidy in acute lymphoblastic leukemia.
    Creasey T; Enshaei A; Nebral K; Schwab C; Watts K; Cuthbert G; Vora A; Moppett J; Harrison CJ; Fielding AK; Haas OA; Moorman AV
    Genes Chromosomes Cancer; 2021 Sep; 60(9):604-615. PubMed ID: 33938069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissecting karyotypic patterns in non-hyperdiploid multiple myeloma: an overview on the karyotypic evolution.
    Jimenez-Zepeda VH; Braggio E; Fonseca R
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):552-8. PubMed ID: 23856591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytogenetics of multiple myeloma.
    Trcić RL; Skelin IK; Sustercić D; Planinc-Peraica A; Ajduković R; Haris V; Kusec R; Begović D
    Coll Antropol; 2010 Mar; 34(1):41-4. PubMed ID: 20432732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperhaploid plasma cell myeloma.
    Hoctor VT; Campbell LJ
    Cancer Genet; 2012; 205(7-8):414-8. PubMed ID: 22868003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromosome abnormalities defined by conventional cytogenetics in plasma cell leukemia: what have we learned about its biology?
    Jimenez-Zepeda VH; Neme-Yunes Y; Braggio E
    Eur J Haematol; 2011 Jul; 87(1):20-7. PubMed ID: 21692850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma.
    Di Martino MT; Guzzi PH; Caracciolo D; Agnelli L; Neri A; Walker BA; Morgan GJ; Cannataro M; Tassone P; Tagliaferri P
    Oncotarget; 2015 Aug; 6(22):19132-47. PubMed ID: 26056083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.
    Decaux O; Lodé L; Magrangeas F; Charbonnel C; Gouraud W; Jézéquel P; Attal M; Harousseau JL; Moreau P; Bataille R; Campion L; Avet-Loiseau H; Minvielle S;
    J Clin Oncol; 2008 Oct; 26(29):4798-805. PubMed ID: 18591550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oligonucleotide-based array CGH as a diagnostic tool in multiple myeloma patients.
    Smetana J; Fröhlich J; Vranová V; Mikulásová A; Kuglik P; Hájek R
    Klin Onkol; 2011; 24 Suppl():S43-8. PubMed ID: 21923064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential repetitive DNA methylation in multiple myeloma molecular subgroups.
    Bollati V; Fabris S; Pegoraro V; Ronchetti D; Mosca L; Deliliers GL; Motta V; Bertazzi PA; Baccarelli A; Neri A
    Carcinogenesis; 2009 Aug; 30(8):1330-5. PubMed ID: 19531770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.
    Sawyer JR; Tian E; Shaughnessy JD; Epstein J; Swanson CM; Stangeby C; Hale CL; Parr L; Lynn M; Sammartino G; Lukacs JL; Stein C; Bailey C; Zangari M; Davies FE; Van Rhee F; Barlogie B; Morgan GJ
    Leukemia; 2017 Mar; 31(3):637-644. PubMed ID: 27694925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis.
    Kamada Y; Sakata-Yanagimoto M; Sanada M; Sato-Otsubo A; Enami T; Suzukawa K; Kurita N; Nishikii H; Yokoyama Y; Okoshi Y; Hasegawa Y; Ogawa S; Chiba S
    Int J Hematol; 2012 Oct; 96(4):492-500. PubMed ID: 22972171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.
    Egan JB; Shi CX; Tembe W; Christoforides A; Kurdoglu A; Sinari S; Middha S; Asmann Y; Schmidt J; Braggio E; Keats JJ; Fonseca R; Bergsagel PL; Craig DW; Carpten JD; Stewart AK
    Blood; 2012 Aug; 120(5):1060-6. PubMed ID: 22529291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients.
    Wu SP; Pfeiffer RM; Ahn IE; Mailankody S; Sonneveld P; van Duin M; Munshi NC; Walker BA; Morgan G; Landgren O
    Clin Cancer Res; 2016 Aug; 22(16):4039-44. PubMed ID: 26847058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.